LYNPARZA (olaparib)

LynparzaTM (olaparib) is a first‐in‐class PARP inhibitor (PARPi) that allows women with BRCA mutated (BRCAm) platinum‐sensitive relapsed high-grade serous ovarian cancer to extend progression‐free survival (PFS).1-3

Prescribing Information

Dose Adjustments

Dose adjustments and/or dose interruptions may be required to manage adverse events such as nausea, vomiting, diarrhoea and anaemia4. Refer to SmPC for more information and specific recommendations.

Dose adjustments with Lynparza
Dose adjustments with Lynparza
Image showing recommended dose reduction from 400mg to 200mg to 100mg as a final reduction
Image showing recommended dose reduction from 400mg to 200mg to 100mg as a final reduction